At UCLA, Dr. David Nathanson is designing new therapies that deal with glioblastoma’s distinctive tumor biology, aiming to beat long-standing remedy challenges.
For the previous 20 years, David Nathanson, PhD, has approached every day with a singular objective: perceive and remedy glioblastoma. That message is acknowledged prominently on his lab’s website, serving as each a mission assertion and fixed reminder of the sufferers who rely on the work occurring inside his lab.
‘I would like that strain,’ mentioned Dr. Nathanson, a professor of molecular and medical pharmacology on the David Geffen Faculty of Medication at UCLA and a member of the UCLA Health Jonsson Comprehensive Cancer Center. ‘Assembly sufferers who’ve primarily been given a demise sentence is extremely troublesome. For years, we made virtually no progress, and plenty of succumbed inside a 12 months. However that’s beginning to change. Now we’re starting to establish targets and potential medication that might make a distinction. With the ability to supply sufferers even a glimmer of hope is inspiring, for them and for all of us working to combat this illness.’
Dr. Nathanson’s journey into science, nevertheless, wasn’t all the time so clear-cut. He grew up in Alaska, captivated by the mysteries of the pure world reasonably than molecular biology. As a teen, he developed a love for flying small planes, a interest that gave him each perspective and a way of self-discipline and focus he would carry into his work. It wasn’t till graduate college at UCLA that he encountered most cancers analysis, the place he was instantly drawn to each the mental problem and the chance to deal with an issue that was as complicated scientifically because it was clinically.
‘That mixture of fixing arduous issues and serving to individuals who really want it was extremely highly effective to me,’ he mentioned.
The pressing want for brand spanking new therapies
Discovering new therapies for mind tumors akin to glioblastoma is urgently wanted. The illness is among the many most deadly human cancers, with a median survival measured in months and solely about 5% of sufferers alive 5 years after analysis.
Progress on this space has been painfully sluggish. Regardless of many years of analysis, greater than 90% of medication examined in scientific trials for glioblastoma have failed.
A part of the problem is that glioblastomas are extremely heterogeneous, that means that focusing on a single pathway usually isn’t sufficient. The tumors additionally reside behind the blood-brain barrier, a pure protection that stops many medication from reaching the tumor at therapeutic ranges.
Additional complicating the issue, many therapies examined in glioblastoma have been initially developed for cancers outdoors the central nervous system.
‘These medication have been designed for lung most cancers, breast most cancers, melanoma, and different cancers, after which examined in glioblastoma,’ Dr. Nathanson mentioned. ‘However these tumors are completely different, each in the place they type and the way they operate. That mismatch has contributed considerably to the excessive failure price.’
A customized method
At UCLA, Dr. Nathanson leads a translational mind tumor program that goals to raised perceive the distinctive biology of every glioblastoma and exploit these variations to design extra exact therapies.
In his lab, he and his staff map the metabolic options and signaling pathways that distinguish one tumor from one other. Even when sufferers share the identical analysis, their tumors can differ dramatically on the molecular and genetic stage. These distinctions assist clarify why a remedy that works for one affected person could fail in one other.
‘Every affected person’s tumor is genetically distinct,’ Dr. Nathanson explains. ‘What we’re attempting to grasp is how these variations drive the tumor, and the way we are able to establish particular vulnerabilities that may be focused therapeutically.’
One such vulnerability that Dr. Nathanson’s lab, together with a number of others, has recognized as a essential molecular driver in lots of glioblastomas is the protein epidermal development issue receptor, or EGFR. Alterations in EGFR happen in additional than half of glioblastomas and play a central position in tumor development, proliferation and metabolism.
Whereas medication that concentrate on EGFR exist already, they have been developed primarily for cancers outdoors the mind. In glioblastoma, nevertheless, the mutations happen in several areas of the receptor, altering how these medication work together with the protein. Many of those therapies additionally wrestle to cross the blood-brain barrier, limiting their skill to achieve tumors within the mind.
‘These challenges imply we are able to’t merely repurpose current EGFR-targeting medication,’ Dr. Nathanson mentioned. ‘We want an method designed particularly for glioblastoma, one that may attain the mind and successfully goal these distinctive mutations.’
A drug constructed for glioblastoma
Fairly than attempting to adapt an current remedy, Dr. Nathanson got down to design a drug engineered particularly for glioblastoma, one that might penetrate the mind, bind the related EGFR mutations, and accomplish that with out overwhelming toxicity.
To realize this, he partnered with neuro-oncologist Timothy Cloughesy, MD, distinguished professor and director of the Neuro-Oncology Program and co-director of the UCLA Mind Tumor Middle, and chemist Michael Jung, PhD, a UCLA distinguished professor of chemistry and biochemistry, who had beforehand helped develop FDA-approved most cancers medication.
The collaboration mixed tumor biology, scientific perception, and medicinal chemistry able to reshaping molecular scaffolds to develop a drug tailor-made to focus on glioblastoma.
‘Designing a remedy for glioblastoma means fixing for each biology and anatomy on the similar time,’ Dr. Nathanson mentioned. ‘It’s a must to perceive the mutation driving the tumor, however you additionally need to respect the distinctive setting of the mind. In case you ignore both one, the remedy gained’t work.’
Working carefully with Dr. Cloughesy’s scientific program, the staff evaluated compounds in patient-derived glioblastoma fashions that extra precisely mirrored the illness because it exists in sufferers. This tight suggestions loop between laboratory discovery and scientific perception accelerated the identification of a candidate able to each penetrating the mind and selectively focusing on EGFR alterations.
The consequence was KTM-101, a purpose-built drug for glioblastoma that’s engineered to penetrate the blood-brain barrier and selectively goal distinctive glioblastoma mutations of EGFR.
From bench to bedside
KTM-101 has now superior into scientific testing. Part I trials demonstrated that the drug is protected and well-tolerated, reaching ranges within the mind believed to be therapeutically significant. Much more encouraging, researchers have noticed early indicators of efficacy in sufferers with superior, late-stage glioblastoma, a setting the place advantages are not often seen.
‘Seeing early indicators of exercise at that stage of the illness is extremely uncommon,’ Dr. Nathanson mentioned. ‘It offers us confidence that the drug is hitting its goal and really making a distinction.’
Subsequent, the staff hopes to maneuver KTM-101 earlier in remedy, when tumors could also be extra weak.
Fairly than viewing KTM-101 as an endpoint, Dr. Nathanson sees it as a part of an ongoing effort to remain forward of a illness identified for adaptation. His laboratory is exploring extra focused methods that anticipate how glioblastoma evolves, with the aim of sustaining tumor management over time.
‘What we’re constructing is not only a single drug,’ Dr. Nathanson mentioned. ‘We’re constructing a platform for designing therapies particularly for the biology of mind tumors. Each iteration teaches us one thing new, and every step strikes us nearer to delivering remedies which can be really tailor-made for sufferers with glioblastoma.’
In the end, he says, the aim is easy however pressing – lengthen the lives of sufferers dealing with this devastating analysis.
Dr. Nathanson credit UCLA’s Mind Tumor Program for enabling the speedy translation of laboratory discoveries into scientific trials. Led by neurosurgeon Linda Liau, MD, PhD, and Dr. Cloughesy, this system brings collectively primary scientists, clinicians, imaging specialists and immunologists in a tightly built-in ecosystem.
‘For a primary scientist, the toughest half is translating discoveries into one thing that really reaches sufferers,’ Dr. Nathanson mentioned. ‘The collaborative infrastructure at UCLA makes that translation doable, permitting us to maneuver promising therapies from the lab to sufferers who want them as shortly as doable.’